Brokerages Set Roche Holding AG (OTCMKTS:RHHBY) Target Price at $40.00

Roche Holding AG (OTCMKTS:RHHBYGet Free Report) has been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $40.00.

Separately, Morgan Stanley cut Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th.

Read Our Latest Stock Report on Roche

Roche Stock Performance

RHHBY opened at $32.60 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.86 and a current ratio of 1.18. The business has a 50-day moving average of $35.50 and a two-hundred day moving average of $35.18. Roche has a 12 month low of $31.77 and a 12 month high of $40.48.

Institutional Investors Weigh In On Roche

Several large investors have recently modified their holdings of the business. Vestor Capital LLC bought a new position in Roche during the 2nd quarter worth $44,000. Wetzel Investment Advisors Inc. acquired a new position in Roche during the 4th quarter worth about $53,000. First Horizon Advisors Inc. lifted its holdings in Roche by 39.4% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,724 shares of the company’s stock worth $58,000 after buying an additional 487 shares during the period. Operose Advisors LLC acquired a new position in shares of Roche in the 3rd quarter valued at about $59,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Roche in the 1st quarter valued at about $103,000.

About Roche

(Get Free Report

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Featured Stories

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with's FREE daily email newsletter.